- PureTech Health said affiliate Vor Biopharma had announced the publication of a paper in a scientific journal supporting its approach to treating cancer via engineered hematopoietic stem cells.

The paper was published in the Proceedings of the National Academy of Medicines.

'Vor's novel approach is designed to reboot the patient's immune system with an infusion of healthy blood stem cells that are protected from the toxic effects of targeted immunotherapies,' PureTech president and head of business strategy Bharatt Chowrira said.

'This approach has the potential to minimize the toxicities associated with immunotherapies and greatly expand the reach of this class of medicines, well beyond what is currently possible.'

'We are excited and encouraged by these results and look forward to Vor's progress in advancing its lead candidate VOR33 and other therapies built around engineered HSCs.'

At 8:23am: [LON:PRTC] PureTech Health Plc share price was +7.25p at 198.25p

Story provided by